Circulating tumor cells in patients with testicular germ cell tumors

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3830-3841

  Nastały, Paulina ^a   Ruf, Christian ^a,b   Becker, Pascal ^b   Bednarz Knoll, Natalia ^a   Stoupiec, Małgorzata ^a   Kavsur, Refik ^a   Isbarn, Hendrik ^a   Matthies, Cord ^b   Wagner, Walter ^b   Höppner, Dirk ^c   Fisch, Margit ^a   Bokemeyer, Carsten ^a   Ahyai, Sascha ^a   Honecker, Friedemann ^a   Riethdorf, Sabine ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Bundeswehrkrankenhaus Hamburg   (Germany)

^c Department of Oncology Haematology and Bone Marrow Transplantation with Section Pneumology University Medical Centre Hamburg Eppendorf ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER STAGING; CHROMOSOME 12P; CIRCULATING TUMOR CELL; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DENSITY GRADIENT CENTRIFUGATION; DISEASE MARKER; EPITHELIUM CELL; FOLLOW UP; GENETIC GAIN; GERM CELL TUMOR; GONADOTROPIN BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SEMINOMATOUS GERMINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; TERATOMA; TUMOR CELL LINE; YOLK SAC TUMOR; CHROMOSOME 12; GENETICS; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROGNOSIS; TESTIS TUMOR; TRISOMY; TUMOR EMBOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 12; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TESTICULAR NEOPLASMS; TRISOMY; YOUNG ADULT;

EID: 84899499852     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2819     Document Type: Article

References (50)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337:242-53.
2. Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP. Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol 2013;12:1-6.
3. Trigo JM, Tabernero JM, Paz-Ares L, García-Llano JL, Mora J, Lianes P, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000;88:162-8. (Pubitemid 30027692)
4. Peckman MJ, Hamilton CR, Horwich A, Hendry WF. Surveillance after orchiectomy for stage 1 seminoma of the testis. Br J Urol 1987;59:343-51.
5. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 2003;21:4092-9. (Pubitemid 46606175)
6. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
7. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-40. (Pubitemid 351596394)
8. Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 2012;61:810-7.
9. Fan Y, Einhorn L, Saxman S, Katz B, Abonour R, Cornetta K. Detection of germ cell tumor cells in apheresis products using polymerase chain reaction. Clin Cancer Res 1998;4:93-8. (Pubitemid 28062882)
10. Hildebrandt MO, Bläser F, Beyer J, Siegert W, Mapara MY, Huhn D, et al. Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase-polymerase chain reaction techniques. Bone Marrow Transplant 1998;22:771-5. (Pubitemid 28488320)
11. Bokemeyer C, Gillis AJ, Pompe K, Mayer F, Metzner B, Schleucher N, et al. Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. J Clin Oncol 2001;19:3029-36. (Pubitemid 32565440)
12. Yuasa T, Yoshiki T, Tanaka T, Isono T, Okada Y. Detection of circulating testicular cancer cells in peripheral blood. Cancer Lett 1999;143:57-62. (Pubitemid 29327190)
13. Hautkappe AL, Lu M, Mueller H, Bex A, Harstrick A, Roggendorf M, et al. Detection of germ-cell tumor cells in the peripheral blood by nested reverse transcription-polymerase chain reaction for alpha-fetoprotein-messenger RNA and beta human chorionic gonadotropin-messenger RNA. Cancer Res 2000;60:3170-4. (Pubitemid 30407913)
14. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005;18:61-79.
15. Cao D, Li J, Guo CC, Allan RW, Humphrey PA. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol 2009;33:1065-77.
16. Looijenga LH, Stoop H, Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003;1:2244-50. (Pubitemid 36538633)
17. Jackson B, Grund C, Winter S, Schmid E, Burki K, Franke W, et al. Formation of cytoskeletal elements during mouse embryogenesis. Intermediate filaments of the cytokeratin type and desmosomes in preimplantation embryos. Differentiation 1980;17:161-79. (Pubitemid 11182897)
18. Jackson B, Grund C, Winter S, Franke WW, Illmensee K. Formation of cytoskeletal elements during mouse embryogenesis. II. Epithelial differentiation and intermediate-sized filaments in early postimplantation embryos. Differentiation 1981;20:203-16. (Pubitemid 12136284)
19. Cheville JC, Rao S, Iczkowski KA, LohseCM, Pankratz VS. Cytokeratin expression in seminoma of the human testis. Am J Clin Pathol 2000;113:583-8. (Pubitemid 30217369)
20. de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 2008;10:1041-8.
21. Anderson R, Schaible K, Heasman J, Wylie C. Expression of the homophilic adhesion molecule, Ep-CAM, in the mammalian germ line. J Reprod Fertil 1999;116:379-84.
22. Dovey SL, Valli H, Hermann BP, Sukhwani M, Donohue J, Castro CA, et al. Eliminating malignant contamination from therapeutic human spermatogonial stem cells. J Clin Invest 2013;123:1833-43.
23. Schönberger S, Okpanyi V, Calaminus G, Heikaus S, Leuschner I, Nicholson JC, et al. EPCAM - a novel molecular target for the treatment of pediatric and adult germ cell tumors. Genes Chromosomes Cancer 2012;52:1-9.
24. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91. (Pubitemid 39095313)
25. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21.
26. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904. (Pubitemid 39383039)
27. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch® system. Clin Cancer Res 2007;13:920-8. (Pubitemid 46340368)
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
29. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994;3:165-73.
30. Looijenga LH, Zafarana G, Grygalewicz B, Summersgill B, Debiec-Rychter M, Veltman J, et al. Role of gain of 12p in germ cell tumour development. APMIS 2003;111:161-71.
31. Zafarana G, Gillis AJ, van Gurp RJ, Olsson PG, Elstrodt F, Stoop H, et al. Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res 2002;62:1822-31. (Pubitemid 34408509)
32. Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009;6:339-51.
33. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013;23:573-81.
34. Michael H, Lucia J, Foster RS, Ulbright TM. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol 2000;24:257-73. (Pubitemid 30078715)
35. Atsü N, Eskiçorapçi S, Uner A, Ekici S, Güngen Y, Erkan I, et al. A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int 2003;92:32-5. (Pubitemid 36843024)
36. Mayer F, Wermann H, Albers P, Stoop H, Gillis AJ, Hartmann JT, et al. Histopathological and molecular features of late relapses in nonseminomas. BJU Int 2011;107:936-43.
37. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 1988;62:1202-6.
38. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I non-seminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995;154:1045-9.
39. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21:1505-12. (Pubitemid 46594103)
40. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010;28:3388-404.
41. International Germ Cell Cancer Collaborative International Group. Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
42. Kara T, Younes M, Erol B, Karcaaltincaba M. Evaluation of testicular vein anatomy with multidetector computed tomography. Surg Radiol Anat 2011;34:341-5.
43. Peeters DJ, Van den Eynden GG, van Dam PJ, Prové A, Benoy IH, van Dam PA, et al. Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer. Br J Cancer 2011;104:1472-7.
44. Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès JP, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 2013;59:1-9.
45. Bednarz-Knoll N, Alix-Panabières C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012;31:673-87.
46. Bednarz-Knoll N, Alix-Panabières C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 2011;13:228-36.
47. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013;59:110-8.
48. Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A, et al. Cell membrane-specific epitopes on CD30: potentially superior targets for immunotherapy. Proc Natl Acad Sci U S A 2005;102:7946-51. (Pubitemid 40781043)
49. Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2013;110:1083-91.
50. Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009;27:2129-36.